Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3–23. https://doi.org/10.2174/2211738507666190122111224.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. https://doi.org/10.1016/j.intimp.2020.106535.

Article  PubMed  CAS  Google Scholar 

McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57:9s–16s. https://doi.org/10.2967/jnumed.115.157834.

Article  PubMed  Google Scholar 

Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96. https://doi.org/10.1186/s12943-023-01801-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, et al. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol. 2005;34(2):535–51. https://doi.org/10.1677/jme.1.01677.

Article  PubMed  CAS  Google Scholar 

Zhu J, Ye L, Sun S, Yuan J, Huang J, Zeng Z. Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle. Aging. 2023;15(23):13738–52. https://doi.org/10.18632/aging.205260.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xiang J, Fang L, Luo Y, Yang Z, Liao Y, Cui J, et al. Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. J Transl Med. 2014;12:320. https://doi.org/10.1186/s12967-014-0320-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang J, Wang L, Xie X. RFC4 promotes the progression and growth of Oral Tongue squamous cell carcinoma in vivo and vitro. J Clin Lab Anal. 2021;35(5):e23761. https://doi.org/10.1002/jcla.23761.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen P, Liu Y, Ma X, Li Q, Zhang Y, Xiong Q, et al. Replication Factor C4 in human hepatocellular carcinoma: a potent prognostic factor associated with cell proliferation. Biosci Trends. 2021;15(4):249–56. https://doi.org/10.5582/bst.2021.01139.

Article  PubMed  CAS  Google Scholar 

Wang XC, Yue X, Zhang RX, Liu TY, Pan ZZ, Yang MJ, et al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. 2019;25(14):4567–79. https://doi.org/10.1158/1078-0432.Ccr-18-3735.

Article  PubMed  CAS  Google Scholar 

Shi Y, Xiong X, Sun Y, Geng Z, Chen X, Cui X, et al. IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m(6) A-dependent manner. Faseb j. 2023;37(10):e23183. https://doi.org/10.1096/fj.202202145RRR.

Article  PubMed  CAS  Google Scholar 

Ji R, Wu C, Yao J, Xu J, Lin J, Gu H, et al. IGF2BP2-meidated m(6)A modification of CSF2 reprograms MSC to promote gastric cancer progression. Cell Death Dis. 2023;14(10):693. https://doi.org/10.1038/s41419-023-06163-7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang J, Xu J, Zheng J. A1BG-AS1 promotes adriamycin resistance of breast cancer by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner. Sci Rep. 2023;13(1):20730. https://doi.org/10.1038/s41598-023-47956-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yan Y, He M, Zhao L, Wu H, Zhao Y, Han L, et al. A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPR(ER) axis. Cell Death Differ. 2022;29(9):1769–89. https://doi.org/10.1038/s41418-022-00963-8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jiao D, Zhang J, Chen P, Guo X, Qiao J, Zhu J, et al. HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1. J Cell Mol Med. 2021;25(1):397–410. https://doi.org/10.1111/jcmm.16090.

Article  PubMed  CAS  Google Scholar 

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2022;1(3):e36. https://doi.org/10.1002/imt2.36.

Article  PubMed  PubMed Central  Google Scholar 

Oshima M, Takayama KI, Yamada Y, Kimura N, Kume H, Fujimura T, et al. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer. Sci Rep. 2023;13(1):19602. https://doi.org/10.1038/s41598-023-46651-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yu L, Li J, Zhang M, Li Y, Bai J, Liu P, et al. Identification of RFC4 as a potential biomarker for pan-cancer involving prognosis, tumour immune microenvironment and drugs. J Cell Mol Med. 2024;28(12):e18478. https://doi.org/10.1111/jcmm.18478.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alaa Eldeen M, Mamdouh F, Abdulsahib WK, Eid RA, Alhanshani AA, Shati AA, et al. Oncogenic potential of replication factor C subunit 4: correlations with tumor progression and assessment of potential inhibitors. Pharmaceuticals. 2024. https://doi.org/10.3390/ph17020152.

Article  PubMed  PubMed Central  Google Scholar 

Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. https://doi.org/10.1016/j.neo.2022.01.001.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aponte PM, Caicedo A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cells Int. 2017;2017:5619472. https://doi.org/10.1155/2017/5619472.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gao W, Wen H, Liang L, Dong X, Du R, Zhou W, et al. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer. Theranostics. 2021;11(6):2564–80. https://doi.org/10.7150/thno.45280.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu L, Tao T, Liu S, Yang X, Chen X, Liang J, et al. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness. Nat Commun. 2021;12(1):2693. https://doi.org/10.1038/s41467-021-22971-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014;74(24):7573–82. https://doi.org/10.1158/0008-5472.Can-14-1140.

Article  PubMed  CAS  Google Scholar 

Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, et al. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47(D1):D529–41. https://doi.org/10.1093/nar/gky1079.

Article